Phase II Study of Revlimid (Lenalidomine), Melphalan, and Dexamethasone (ReMeDex) for Newly Diagnosed Multiple Myeloma Patients Not Undergoing Autologous Transplantation.

Trial Profile

Phase II Study of Revlimid (Lenalidomine), Melphalan, and Dexamethasone (ReMeDex) for Newly Diagnosed Multiple Myeloma Patients Not Undergoing Autologous Transplantation.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Oct 2011 Planned end date changed from 1 Dec 2014 to 1 Oct 2011 as reported by ClinicalTrials.gov.
    • 28 Oct 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top